General Information

Sacubitril Impurities and Sacubitril 

Daicel Pharma synthesizes high-quality Sacubitril impurities like (2R,4R)-Sacubitril, (2R,4S)-Sacubitril, (2S,4S)-Sacubitril, 3-Methyl Pyrrolidione (for Sacubitril), Sacubitril amino acid impurity, Sacubitril Ene impurity, and more, which are crucial in the analysis of the quality, stability, and biological safety of the active pharmaceutical ingredient Sacubitril. Moreover, Daicel Pharma offers custom synthesis of Sacubitril impurities and delivers them globally.

Sacubitril [CAS: 149709-62-6] is a prodrug that inhibits neprilysin (NEP). It is a component of the drug containing Sacubitril/valsartan, a novel class of drugs called angiotensin receptor neprilysin inhibitors (ARNI). It reduces the risk of cardiovascular death in patients with chronic heart failure.

Sacubitril: Use and Commercial Availability  

Sacubitril/valsartan is for patients with chronic heart failure with reduced ejection fraction (HFrEF) who continue to experience symptoms despite receiving optimal medical treatment with ACE inhibitors, ARBs, beta-blockers, and MRA. It is a substitute for ACE inhibitors or other ARBs to decrease the risk of hospitalization and death due to cardiovascular events. It is also used with other heart failure treatments. Sacubitril/valsartan is available under the trade name Entresto.

Sacubitril Structure and Mechanism of Action

The chemical name of Sacubitril is (2R,4S)-5-(Biphenyl-4-yl)-4-[(3-carboxypropionyl)amino]-2-methylpentanoic acid ethyl ester. Its chemical formula is C₂₄H₂₉NO₅, and its molecular weight is approximately 411.5 g/mol.

Sacubitril inhibits neprilysin, combines with angiotensin receptor blocker Valsartan and helps in vasodilation and natriuresis. It reduces the risk of heart failure in patients having chronic heart failure.

Sacubitril Impurities and Synthesis

During the production¹ of Sacubitril, impurities form that may be harmful to patients. These impurities are due to factors such as reaction conditions, the quality of starting materials, and the presence of other reaction intermediates. Purification methods, such as chromatography and crystallization, are used to remove these impurities and ensure the purity and safety of the final product.

Daicel provides a Certificate of Analysis (CoA) for Sacubitril impurity standards, including (2R,4R)-Sacubitril, (2R,4S)-Sacubitril, (2S,4S)-Sacubitril, 3-Methyl Pyrrolidione (for Sacubitril), Sacubitril amino acid impurity, Sacubitril Ene impurity, and more. The CoA is issued from a cGMP-compliant analytical facility and contains complete characterization data, such as 1H NMR, 13C NMR, IR, MASS, and HPLC purity². Additional characterization data, such as 13C-DEPT and CHN, can be provided upon request. Daicel can also prepare any unknown Sacubitril impurity or degradation product and offer labeled compounds to quantify the efficacy of Sacubitril. Daicel offers Sacubitril – D4 and Sacubitril metabolite LBQ 657 – D4 / Sacubitrilat/D4 (New), deuterium-labeled Sacubitril standards, used in bio-analytical research, such as BA/BE studies. We give a complete characterization report on delivery.